Schedule of Events

Friday, January 17
1:00 PM – 3:00 PM APSARD Board Meeting
3:00 PM – 7:00 PM APSARD Registration
5:30 PM – 7:30 PM Welcome/Opening Plenary: Perinatal and Early Life Issues in ADHD

Speakers: Joseph Biederman, M.D.- Chair, Lee Cohen, M.D., and Mark Mahone, Ph.D

7:30 PM – 9:00 PM Reception and Poster Presentations
Saturday, January 18
7:00 AM – 6:00 PM APSARD Registration
7:00 AM- 8:00 AM International Breakfast
8:00 AM – 8:45 AM President’s Summary: State of APSARD
Plenary Session: New FDA Guidance and Initiatives – Overview and Discussion.
Panel discussion to follow both plenary sessions*
9:00 AM – 10:15 AM




1. New FDA Guidance for ADHD Drug Development: Rationale, Requirements and Implications for Trial Design

Speakers: Stephen Faraone, Ph.D – Co-Chair, Jeffrey Newcorn, M.D.- Co-Chair, Tiffany Farchione, M.D., and Tom Laughren, M.D.

Panelists: Len Adler, M.D, Matthew Brams, M.D., Steve Faraone, Ph.D and Sharon Wigal, Ph.D

10:15 AM – 11:15 AM 2. FDA Comments on the the Potential Role for Abuse-Deterrent Formulations of Central Nervous System Stimulants

Speakers: Stephen Faraone, Ph.D – Co-Chair, Jeffrey Newcorn, M.D.- Co-Chair, and Marta Sokolowska, Ph.D

Panelists: David Baker, M.B.A. Frances Levin, M.D. and Brooke Molina, Ph.D

11:15 AM – 11:45 AM Coffee Break
11:45 AM – 12:30 PM Lifetime Achievement Plenary
12:30 PM – 1:00 PM Data Blitz Session
12:30 PM – 2:30 PM Poster Session with Lunch
Symposium Sessions:
2:30 PM – 4:30 PM ADHD and Autism: New Insights on Their Relationship

Speakers: Steven Pliszka, M.D. – Chair, Antonia Hardan, M.D., Nanda Labregts-Rommelse, Ph.D, and Benjamin Yerys, Ph.D

2:30 PM – 4:30 PM Are Differences in Long-Acting  Stimulant  Formulations Clinically Meaningful?

Speakers: Tom Spencer, M.D. – Chair, Andrew Babiskin, Ph.D, Ann Childress, M.D. and Roberto Gomeni, Ph.D

Discussant: Joseph Biederman, M.D.

4:30 PM – 5:00 PM Coffee Break
5:00 PM – 6:15 PM Meet the Experts Sessions
6:30 PM – 7:30 PM Reception
Sunday, January 19
7:30 AM – 4:00 PM APSARD Registration
8:15 AM – 9:00 AM APSARD Business Meeting
9:00 AM – 10:45AM Plenary Session: Comparative Efficacy and Tolerability of ADHD Medications in
Children/Adolescents and Adults: What is the Evidence and What Are the Implications for Guidelines, Algorithm Development, and Clinical Care
*Panel discussion to follow*

Speakers: Jeffrey Newcorn, M.D. – Chair, and Samuele Cortese, M.D., Ph.D

Panelists: Tanya Froelich, M.D., David Goodman, M.D. and Mark Stein, Ph.D

10:45 AM – 11:00AM Coffee Break
10:45 AM – 12:30PM Plenary Session: Understanding Barriers of Care in ADHD the Report of the Office of the Inspector General

Speakers: Joseph Biederman, M.D.- Chair, Joseph Blader, Ph.D, Peter Jensen, M.D. and Jamila Murga, MPA, RN

Lunch Session and Discussion Groups:
12:30 PM – 2:30 PM Too Much or Not Enough? Managing Complex Pharmacology in Difficult Cases

Speakers: Steven Pliszka, M.D. – Chair and Craig Surman, M.D.

12:30 PM – 2:30 PM Role of Neuropsychology in Assessment of ADHD: Clinical Discussion

Speakers: Russell Schachar, M.D. – Chair, Kevin Antshel, Ph.D, Russel Barkley, Ph.D, and Mark Mahone, Ph.D

Symposium Sessions:
2:30 PM – 4:30 PM Sleep Challenges in ADHD

Speakers: Mark Stein, Ph.D- Chair, Stephen Becker, Ph.D, Emma Sciberras, Ph.D, Craig Surman, M.D. and Margaret Weiss, M.D., Ph.D 

2:30 PM – 4:30 PM ADHD and Cannabis/CBD

Speakers:  Frances Levin, M.D. – Chair, Sam Chang, FRCP(C), Kevin Hill, M.D., Paula Riggs, M.D. and Elise Weerts, Ph.D